Advances on the treatment of relapsed or refractory extranodal NK/T-cell lymphoma, nasal type
-
摘要: 鼻型结外NK/T细胞淋巴瘤(ENKTL)是侵袭性非霍奇金淋巴瘤的一种，临床预后较差。尽管目前临床上以左旋门冬酰胺酶为核心的多种化疗方案的应用使患者预后得到明显改善，但仍有部分患者治疗后出现复发或进展为难治性疾病。近年来，免疫调节治疗、单克隆抗体、信号通路靶向治疗、基因表达及表观调控等一系列治疗措施的应用为复发难治性ENKTL提供了新的方向。同时，相关药物的联合使用也取得了一定的成果，其在复发难治性ENKTL中得到应用并提高了患者的生存率和生活质量。
-
关键词:
- 鼻型结外NK/T细胞淋巴瘤 /
- 复发难治性 /
- 靶向治疗 /
- 免疫治疗 /
- 联合治疗
Abstract: Extranodal NK/T-cell lymphoma(ENKTL), nasal type is an aggressive form of non-Hodgkin lymphoma with a poor prognosis. Although the current multiple L-asparaginase-based therapy options have clearly improved outcomes in patients, a significant proportion of patients would relapse or progress with treatment-refractory disease after initial therapy. In recent years, application of multiple therapeutic measures, such as immunomodulatory treatments, monoclonal antibodies, targeting signaling pathways and epigenetic modifications, provides novel directions for the treatment of these relapsed or refractory patients. Concurrently, combination therapies of related drugs have also acquired some achievements, which have been applied in relapsed or refractory ENKTL and improve the survival and quality of life. -
-
[1] 杨双双, 巴云鹏, 姜国忠. CD20阳性的结外鼻型NK/T细胞淋巴瘤11例临床分析[J]. 临床耳鼻咽喉头颈外科杂志, 2021, 35(5): 436-440. doi: 10.13201/j.issn.2096-7993.2021.05.012
[2] 刘鹏利, 程泽星, 陆美萍, 等. 120例头颈部鼻型结外NK/T细胞淋巴瘤误诊分析[J]. 临床耳鼻咽喉头颈外科杂志, 2020, 34(1): 73-78. doi: 10.13201/j.issn.1001-1781.2020.01.018
[3] Philippe Walter L, Couronné L, Jais JP, et al. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: a French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire(SFGM-TC)[J]. Am J Hematol, 2021, 96(7): 834-845. doi: 10.1002/ajh.26200
[4] Kim SJ, Yoon DH, Kim JS, et al. Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase Ⅱ trial[J]. Cancer Res Treat, 2020, 52(2): 374-387. doi: 10.4143/crt.2019.198
[5] Huang HQ, Zhu J, Yao M, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study[J]. J Hematol Oncol, 2021, 14(1): 25. doi: 10.1186/s13045-020-01020-y
[6] Aeppli S, Driessen C, Graf L, et al. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma(ENKL)and meningeosis leukemica with daratumumab[J]. Hematol Oncol, 2018, 36(4): 713-714. doi: 10.1002/hon.2533
[7] Kawai H, Ando K, Maruyama D, et al. Phase Ⅱ study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma[J]. Cancer Sci, 2021, 112(6): 2426-2435. doi: 10.1111/cas.14906
[8] Wang L, Bi XW, Zhu YJ, et al. IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma[J]. Cancer Commun, 2018, 38(1): 62.
[9] De Mel S, Hue SS, Jeyasekharan AD, et al. Molecular pathogenic pathways in extranodal NK/T cell lymphoma[J]. J Hematol Oncol, 2019, 12(1): 33. doi: 10.1186/s13045-019-0716-7
[10] Nairismägi M, Gerritsen ME, Li ZM, et al. Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma[J]. Leukemia, 2018, 32(5): 1147-1156. doi: 10.1038/s41375-017-0004-x
[11] Liu JM, Liang L, Li D, et al. JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T cell lymphoma, nasal type[J]. Oncol Rep, 2019, 41(6): 3219-3232.
[12] Song TL, Nairismägi ML, Laurensia Y, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma[J]. Blood, 2018, 132(11): 1146-1158. doi: 10.1182/blood-2018-01-829424
[13] Rong QX, Wang F, Guo ZX, et al. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma[J]. Mol Cancer, 2021, 20(1): 80. doi: 10.1186/s12943-021-01374-y
[14] Gao LM, Zhang YH, Shi XL, et al. The role of PD-L1 expression in prediction and stratification of recurrent or refractory extranodal natural killer/T-cell lymphoma[J]. Front Oncol, 2022, 12: 821918. doi: 10.3389/fonc.2022.821918
[15] Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma[J]. Blood, 2018, 131(8): 888-898. doi: 10.1182/blood-2017-08-802470
[16] 刘菊梅, 梁丽, 黄思夏, 等. 抑癌基因PRDM1在结外NK/T细胞淋巴瘤-鼻型中的表达及其与PI3K/AKT通路活化的关系[J]. 中华血液学杂志, 2018, 39(12): 1010-1016. doi: 10.3760/cma.j.issn.0253-2727.2018.12.008
[17] Lu LS, Fu XR, Li ZM, et al. Platelet-derived growth factor receptor alpha(PDGFRα)is overexpressed in NK/T-cell lymphoma and mediates cell survival[J]. Biochem Biophys Res Commun, 2018, 504(2): 525-531. doi: 10.1016/j.bbrc.2018.08.181
[18] Zhang HY, Lu JP, Jiao Y, et al. Aspirin inhibits natural killer/T-cell lymphoma by modulation of VEGF expression and mitochondrial function[J]. Front Oncol, 2018, 8: 679.
[19] Zhang Y, Xiang JJ, Zhu N, et al. Curcumin in combination with omacetaxine suppress lymphoma cell growth, migration, invasion, and angiogenesis via inhibition of VEGF/Akt signaling pathway[J]. Front Oncol, 2021, 11: 656045. doi: 10.3389/fonc.2021.656045
[20] 张克娟. 西达本胺治疗难治性结外NK/T细胞淋巴瘤的临床效果及安全性分析[J]. 临床医药文献电子杂志, 2019, 6(57): 55-58. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWX201957038.htm
[21] He XH, Gao Y, Li ZM, et al. Review on natural killer/T-cell lymphoma[J]. Hematol Oncol, 2023, 41(2): 221-229. doi: 10.1002/hon.2944
[22] Yi W, Yang TX, Lin SS, et al. New approaches for treatment of advanced extranodal NK/T-cell lymphoma[J]. Cancer Manag Res, 2022, 14: 401-407. doi: 10.2147/CMAR.S328846
[23] Burke B, Eden C, Perez C, et al. Inhibition of histone deacetylase(HDAC)enhances checkpoint blockade efficacy by rendering bladder cancer cells visible for T cell-mediated destruction[J]. Front Oncol, 2020, 10: 699. doi: 10.3389/fonc.2020.00699
[24] Haverkos BM, Alpdogan O, Baiocchi R, et al. Nanatinostat(nstat)and valganciclovir(VGCV)in relapsed/refractory(R/R)Epstein-Barr virus-positive(EBV+)lymphomas: final results from the phase 1b/2 VT3996-201 study[J]. Blood, 2021, 138(Supplement 1): 623. doi: 10.1182/blood-2021-152603
[25] Liu JM, Liang L, Huang SX, et al. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis[J]. Hum Pathol, 2019, 83: 166-176. doi: 10.1016/j.humpath.2018.08.025
[26] Zhang L, Wei Y, Yan XW, et al. Survivin is a prognostic marker and therapeutic target for extranodal, nasal-type natural killer/T cell lymphoma[J]. Ann Transl Med, 2019, 7(14): 316. doi: 10.21037/atm.2019.06.53
[27] 陈林会, 李冰妍, 梁天嵩, 等. 放化疗联合程序性死亡受体1抗体治疗中晚期NK/T细胞淋巴瘤的疗效分析[J]. 肿瘤基础与临床, 2021, 34(3): 215-218. doi: 10.3969/j.issn.1673-5412.2021.03.008
[28] Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study[J]. Blood, 2020, 136(24): 2754-2763. doi: 10.1182/blood.2020007247
[29] 刘渊博, 袁晓莉, 马荣军, 等. 程序性死亡受体1抑制剂联合化疗治疗初治Ⅲ/Ⅳ期结外NK/T细胞淋巴瘤的效果和安全性[J]. 中华医学杂志, 2021, 101(16): 1178-1181.
[30] Tao R, Fan L, Song YP, et al. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial(ORIENT-4)[J]. Signal Transduct Target Ther, 2021, 6(1): 365. doi: 10.1038/s41392-021-00768-0
[31] Lipsitt AE, Hung JY, Langevin AM. Atezolizumab in combination with intrathecal chemotherapy and radiation for treatment of isolated cerebral nervous system relapse in a patient with extranodal NK/T cell lymphoma: a case report[J]. J Med Case Rep, 2021, 15(1): 1-6. doi: 10.1186/s13256-020-02580-w
[32] Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors(HDACi)for the treatment of cancer: achieving the full therapeutic potential of HDACi[J]. Front Oncol, 2018, 8: 92. doi: 10.3389/fonc.2018.00092
[33] Xu JY, Xu XH, Chen JY, et al. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: a case report[J]. Medicine(Baltimore), 2021, 100(10): e24824.
[34] Xiong J, Cui BW, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma[J]. Cancer Cell, 2020, 37(3): 403-419. e6. doi: 10.1016/j.ccell.2020.02.005
[35] 韩为东, 张亚晶. CAR-T细胞治疗淋巴瘤——我们仍然在路上[J]. 临床血液学杂志, 2022, 35(9): 612-615. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.09.002
[36] 舒畅, 杜艾桦. 恶性血液病患者CAR-T细胞治疗相关感染的现状与管理[J]. 临床血液学杂志, 2022, 35(7): 529-533, 538. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.07.016
[37] Zheng MJ, Yu LY, Hu JJ, et al. Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer/T cell lymphoma[J]. Transl Oncol, 2020, 13(5): 100770.
[38] Kim WS, Oki Y, Kim SJ, et al. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study[J]. Ann Hematol, 2021, 100(10): 2529-2539.
[39] Hu BY, Oki Y. Novel immunotherapy options for extranodal NK/T-cell lymphoma[J]. Front Oncol, 2018, 8: 139.
[40] Ando M, Ando J, Yamazaki S, et al. Long-term eradication of extranodal natural killer/T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo[J]. Haematologica, 2020, 105(3): 796-807.
-
计量
- 文章访问数: 1036
- PDF下载数: 474
- 施引文献: 0
下载: